Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
This study aims to evaluate the safety and effectiveness of Enavogliflozin 0.3 mg, an SGLT2 inhibitor, in patients with amyloid cardiomyopathy. Participants will take both the study drug and a placebo in two separate periods, with a wash-out period in between. The goal is to determine whether Enavogliflozin is safe and effective for treating amyloid cardiomyopathy.
Epistemonikos ID: 5b58203db0c2fa74f578915d9aed820c1169a451
First added on: Nov 22, 2025